Download PDF

1. Company Snapshot

1.a. Company Description

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States.The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder.It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases.


In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy.Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis.The company was incorporated in 1986 and is based in Cranbury, New Jersey.

Show Full description

1.b. Last Insights on PTN

Palatin Technologies' recent performance was driven by several positive developments. The company closed an upsized $18.2 million public offering, with the full exercise of the underwriters' over-allotment option, providing a strengthened balance sheet. Additionally, Palatin regained compliance with NYSE American listing standards, and its common stock resumed trading under the symbol "PTN" on November 12, 2025. The company's obesity pipeline is advancing, with PL7737 IND-enabling toxicology underway and planned IND submission and clinical trial initiation in the first half of 2026. A research collaboration with Boehringer Ingelheim for retinal diseases yielded a $6.5 million milestone payment.

1.c. Company Highlights

2. Palatin's Q2 FY2026 Earnings: Progress in Obesity Programs

Palatin reported a net loss of $7.3 million or $2.86 per share for the second quarter of fiscal year 2026. The actual EPS came in worse than estimates, which were at -$2.35333. Operating expenses for the quarter were $7.4 million, with approximately $2 million in one-time expenses that will not be repeated in future quarters. The company's cash position improved after completing an $18.2 million public offering, with net proceeds of $16.9 million expected to support the advancement of obesity programs and provide working capital.

Publication Date: Mar -07

📋 Highlights
  • Net Loss and Capital Raise:: Palatin reported a Q2 2026 net loss of $7.3M ($2.86/share), but raised $16.9M net proceeds from an $18.2M public offering to regain NYSE compliance.
  • Drug Development Progress:: PL-7737, an oral melanocortin-4 agonist, is in IND-enabling toxicology, with IND submission and Phase I trial planned for H1 2026.
  • Revenue from Sublicensing:: $3.8M upfront revenue expected from PL9643 (MC1R agonist) to be recognized in Q1 2026.
  • Cash Runway Extension:: Operating expenses totaled $7.4M (Q2 2026), with $2M in one-time costs; cash runway now extends beyond Q1 2027.
  • Future Clinical Milestones:: Phase I SAD/MAD trials for oral small molecule and long-acting peptide to conclude by 2026–2027, paving the way for Phase II/III studies in 2027.

Development Progress

Palatin is advancing a portfolio of proprietary melanocortin-4 receptor agonists, initially targeted at rare neuroendocrine obesity disorders. The lead oral small molecule, PL-7737, is progressing through IND-enabling toxicology studies, with an expected IND submission and Phase I trial initiation in the first half of 2026. According to Carl Spana, they have sufficient cash on hand to move forward with Phase I SAD/MAD studies for the oral small molecule and long-acting peptide, with data expected by year-end and in the first half of next year, respectively.

Obesity Programs and Future Plans

The company expects to receive approximately $3.8 million in upfront consideration from the sublicensing of PL9643, a selective melanocortin-1 receptor agonist, which will be recognized as license revenue in the quarter ending March 31, 2026. Palatin views its oral small molecule and once-weekly injectable as complementary, each suited for different patient populations. The company anticipates that the weekly injectable peptide will have higher efficacy, but both products will be necessary for long-term management of chronic obesity indications.

Valuation and Growth Prospects

Analysts estimate next year's revenue growth at 104.6%. The current P/S Ratio is 69.57, indicating a high valuation relative to sales. The EV/EBITDA ratio is -63.73, suggesting that the company's enterprise value is not justified by its current EBITDA. With a significant revenue growth expected, the current valuation may be justified if the company can execute on its plans. However, the high valuation multiples indicate that the stock price has already factored in a significant amount of growth, leaving limited room for further upside.

Combination Therapy and Life Cycle Management

Regarding the combination of GLP-1, Carl Spana noted they've been working on combining these mechanisms for some time and have done clinical trials looking at the interaction. With incretin-based therapies becoming more common, clinicians may want to combine mechanisms, particularly for severe hyperphagia cases. Palatin is positioning itself for life cycle management by exploring combination therapy, which is likely to be used long-term.

3. NewsRoom

Card image cap

Palatin Technologies Q2 Earnings Call Highlights

Feb -19

Source: defenseworld.net

Card image cap

Palatin Technologies, Inc. (PTN) Q2 2026 Earnings Call Transcript

Feb -17

Source: seekingalpha.com

Card image cap

Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

Feb -17

Source: prnewswire.com

Card image cap

Why Are Palatin Technologies (PTN) Shares Spiking After-Hours?

Dec -11

Source: feeds.benzinga.com

Card image cap

Here Are Wednesday’s Top Wall Street Analyst Upgrades and Downgrades: American Eagle Outfitters, Equinix, Garmin, Honeywell, Uber, Wendy’s and More

Dec -03

Source: 247wallst.com

Card image cap

Palatin Technologies, Inc. (PTN) Q1 2026 Earnings Call Transcript

Nov -13

Source: seekingalpha.com

Card image cap

Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

Nov -13

Source: prnewswire.com

Card image cap

Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option

Nov -12

Source: prnewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (8.50%)

6. Segments

Melanocortin Receptor System

Expected Growth: 8.5%

The 8.5% growth of Melanocortin Receptor System from Palatin Technologies, Inc. is driven by increasing demand for novel treatments of female sexual dysfunction, growing awareness of unmet medical needs, and Palatin's strong pipeline of melanocortin-based therapies.

7. Detailed Products

Bremelanotide

A melanocortin receptor agonist for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women

PL-8177

A melanocortin receptor agonist for the treatment of inflammatory bowel disease (IBD)

PL-8331

A melanocortin receptor agonist for the treatment of asthma

8. Palatin Technologies, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Palatin Technologies, Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies for the conditions it targets.

Bargaining Power Of Customers

Palatin Technologies, Inc. has a low bargaining power of customers due to its strong relationships with healthcare providers and patients.

Bargaining Power Of Suppliers

Palatin Technologies, Inc. has a moderate bargaining power of suppliers due to its reliance on a few key suppliers for raw materials and manufacturing services.

Threat Of New Entrants

Palatin Technologies, Inc. has a high threat of new entrants due to the attractiveness of the biotechnology industry and the potential for new companies to enter the market.

Intensity Of Rivalry

Palatin Technologies, Inc. operates in a highly competitive industry with many established players, leading to a high intensity of rivalry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 88.68%
Debt Cost 3.95%
Equity Weight 11.32%
Equity Cost 8.28%
WACC 4.44%
Leverage 783.74%

11. Quality Control: Palatin Technologies, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Arcus Biosciences

A-Score: 4.4/10

Value: 6.4

Growth: 3.6

Quality: 4.8

Yield: 0.0

Momentum: 9.0

Volatility: 2.7

1-Year Total Return ->

View Full Report
Stock-Card
Lexicon Pharmaceuticals

A-Score: 4.2/10

Value: 6.9

Growth: 3.2

Quality: 4.4

Yield: 0.0

Momentum: 10.0

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
Agenus

A-Score: 4.1/10

Value: 9.4

Growth: 2.1

Quality: 4.6

Yield: 0.0

Momentum: 7.5

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Palatin Technologies

A-Score: 3.4/10

Value: 6.0

Growth: 0.0

Quality: 4.7

Yield: 0.0

Momentum: 10.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Chimerix

A-Score: 3.4/10

Value: 6.2

Growth: 3.6

Quality: 5.0

Yield: 0.0

Momentum: 5.0

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
Fate Therapeutics

A-Score: 3.1/10

Value: 8.0

Growth: 4.0

Quality: 4.6

Yield: 0.0

Momentum: 1.0

Volatility: 1.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

22.11$

Current Price

22.11$

Potential

-0.00%

Expected Cash-Flows